BioCentury
ARTICLE | Financial News

Autolus proposes IPO terms

June 8, 2018 1:09 PM UTC

Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ. In a regulatory filing Friday, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS representing one ordinary share.

At the $16 midpoint, Autolus would raise $125 million and would be valued at $604.4 million. Underwriters are Goldman Sachs, Jefferies, Wells Fargo and William Blair...

BCIQ Company Profiles

Autolus Therapeutics plc